{
  "actions": [
    {
      "acted_at": "2017-05-04", 
      "action_code": "10000", 
      "references": [], 
      "text": "Introduced in Senate", 
      "type": "action"
    }, 
    {
      "acted_at": "2017-05-04", 
      "action_code": "", 
      "committees": [
        "SSHR"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Read twice and referred to the Committee on Health, Education, Labor, and Pensions.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "s1049-115", 
  "bill_type": "s", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "Senate Health, Education, Labor, and Pensions", 
      "committee_id": "SSHR"
    }
  ], 
  "congress": "115", 
  "cosponsors": [
    {
      "bioguide_id": "Y000064", 
      "district": null, 
      "name": "Young, Todd C.", 
      "original_cosponsor": true, 
      "sponsored_at": "2017-05-04", 
      "state": "IN", 
      "title": "Sen", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2017-05-04", 
  "number": "1049", 
  "official_title": "A bill to allow the Secretary of Health and Human Services to require that risk evaluation and mitigation strategies for certain drugs include communication plans that provide information about drug formulations or properties described in the drug labeling.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "s934-115", 
      "identified_by": "CRS", 
      "reason": "related", 
      "type": "bill"
    }
  ], 
  "short_title": "Opioid Addiction Risk Transparency Act", 
  "sponsor": {
    "bioguide_id": "H001076", 
    "district": null, 
    "name": "Hassan, Margaret Wood", 
    "state": "NH", 
    "title": "Sen", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2017-05-04", 
  "subjects": [
    "Drug safety, medical device, and laboratory regulation", 
    "Drug therapy", 
    "Health", 
    "Health personnel"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced in Senate", 
    "date": "2017-05-04T04:00:00Z", 
    "text": "Opioid Addiction Risk Transparency Act\n\nThis bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "A bill to allow the Secretary of Health and Human Services to require that risk evaluation and mitigation strategies for certain drugs include communication plans that provide information about drug formulations or properties described in the drug labeling.", 
      "type": "official"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Opioid Addiction Risk Transparency Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Opioid Addiction Risk Transparency Act", 
      "type": "short"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Opioid Addiction Risk Transparency Act", 
      "type": "display"
    }
  ], 
  "updated_at": "2019-04-18T16:35:47Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/115/s/BILLSTATUS-115s1049.xml"
}